The estimated Net Worth of Paula Soteropoulos is at least $1.67 Million dollars as of 13 June 2024. Ms. Soteropoulos owns over 2,220 units of uniQure N.V stock worth over $110,510 and over the last 8 years she sold QURE stock worth over $1,330,943. In addition, she makes $230,005 as Non-Executive Independent Director at uniQure N.V.
Paula has made over 18 trades of the uniQure N.V stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 2,220 units of QURE stock worth $11,411 on 13 June 2024.
The largest trade she's ever made was exercising 2,061,861 units of uniQure N.V stock on 26 September 2019 worth over $14,536,120. On average, Paula trades about 80,023 units every 86 days since 2017. As of 13 June 2024 she still owns at least 20,203 units of uniQure N.V stock.
You can see the complete history of Ms. Soteropoulos stock trades at the bottom of the page.
Paula Soteropoulos serves as Non-Executive Independent Director of the Company. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. Since March 2020, she serves as Strategic Advisor to 5AM Ventures and is Executive Chairman of a 5AM Venture NewCo. From January 2015 through September 2019, she served as President and Chief Executive Officer of Akcea Therapeutics (NASDAQ: AKCA). From July 2013 to December 2014, she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013, most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a Bachelor of Science degree in chemical engineering and a Master of Science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.
As the Non-Executive Independent Director of uniQure N.V, the total compensation of Paula Soteropoulos at uniQure N.V is $230,005. There are 13 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of $4,719,960.
Paula Soteropoulos is 52, she's been the Non-Executive Independent Director of uniQure N.V since . There are 10 older and 4 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
Paula's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos, and William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
uniQure N.V executives and other stock owners filed with the SEC include: